Biotechnology
EDGC (Eone Diagnomics Genome Center) recruits Sam Martin, Vice President of Overseas Business Development... to "accelerate entering the overseas market"
* An expert from Invitae and Ambry Genetics, U.S. genome analysis companies * EDGC states, "We will expand the overseas genome analysis market and advance into the global liquid biopsy technology market by recruiting a global talent in the genome field" * Worked in a non-profit research orga...
2022-09-13 21:00
1612
Turn Biotechnologies launches eTurna™ delivery platform designed specifically to enable nucleic acid therapeutics
The proprietary platform is versatile, equally effective with different cargoes, routes of administration MOUNTAIN VIEW, Calif., Sept. 13, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today ann...
2022-09-13 20:38
1906
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome
GAITHERSBURG, Md. and SHANGHAI, Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 (...
2022-09-13 20:00
2224
AO Foundation acquires RIMASYS to advance the surgical education ecosystem of the future
DAVOS, Switzerland and COLOGNE, Germany, Sept. 13, 2022 /PRNewswire/ -- The AO
Foundation and RIMASYS are pleased to announce that they have taken their
strategic partnership to the next level with a full-stake investment by the AO
in RIMASYS.
2022-09-13 18:00
1751
TikoMed's ILB(R) inhibits cell infection by coronaviruses and modulates reactive cytokine release from microglia in vitro
Adds further support for its broad-spectrum mechanism of action following other recent TBI, ALS and tropical virus studies VIKEN, Sweden, Sept. 13, 2022 /PRNewswire/ -- TikoMed today announced the inclusion in bioRxiv* of an in vitro study evaluating the ability of the company's lead drug candid...
2022-09-13 16:08
1681
Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022
* In first line treatment of advanced or metastatic G/GEJ cancer, early interim data of the first 15 patients with measurable disease receiving the combination of TST001 (Osemitamab) with CAPOX demonstrated a partial response rate of 73.3% and a disease control rate of 100% per RECIST1.1. * B...
2022-09-13 08:00
2411
Aldatu Biosciences Adds Another Outbreak Disease to Pandemic Preparedness Portfolio
BOSTON, Sept. 13, 2022 /PRNewswire/ -- Aldatu Biosciences, a biotechnology company developing molecular diagnostic assays and products based on gold standard real-time PCR, today announced it has been awarded a$3 Million Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the ...
2022-09-13 00:33
1557
DarwinHealth Publication Reports Step-by-Step Protocol for its Tumor Checkpoint-Based, Compound-to-Clinic (C2C) Cancer Drug Discovery Pipeline: Elucidates a Patient-to-Model-to-Patient (PMP) Roadmap for Precision- and Mechanism-Based Identification and Clinical Validation of Novel, Investigational and FDA-Approved Therapeutic Agents Targeting Tumor Regulatory Architecture
NEW YORK, Sept. 13, 2022 /PRNewswire/ -- DarwinHealth, Inc., ( www.DarwinHealth.com) a New York-based biotechnology and cancer drug discovery company announces theSeptember 9, 2022 online publication in Current Protocols (Wiley Science) of their proprietary cancer drug discovery and validation pi...
2022-09-13 00:26
2001
EpiVax Secures Additional Funding from FDA for Immunogenicity Risk Assessment for Biosimilar Products
PROVIDENCE, R.I., Sept. 13, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce the award of a two-year,$2 million grant from the FDA's Office of Center for Drug Evaluation and Research (CDER) to validate a method for immunogenicity risk assessment of host cell proteins (HCP) for ...
2022-09-13 00:24
1859
Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011)
* Preliminary observations in Non-Small Cell Lung Cancer ("NSCLC") support advancing to the registrational stage of the trial; anticipate full interim data set in 4Q'22 * Undifferentiated Pleomorphic Sarcoma ("UPS") and osteosarcoma will advance to Phase 2, part 2 enrollment, which is anticip...
2022-09-12 23:32
2057
Origin Agritech Announces Addition to Two FTSE Russell Equity Indices
BEIJING, Sept. 12, 2022 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), an agriculture technology company, announced today that effectiveSeptember 16, 2022, Origin Agritech will be added two new equity indices, the FTSE Micro Cap Index and the FTSE Total Cap Index...
2022-09-12 20:45
2256
Brain Navi Biotechnology Announced Partnership with Distributor, Medtreq Medical Equipment, to enter the Middle East and Egypt with NaoTrac Neurosurgical Robot
HSINCHU, Sept. 12, 2022 /PRNewswire/ -- Brain Navi, the leading surgical robot manufacture inTaiwan, announced a strategic partnership with distributor, Medtreq Medical Equipment, to expand the distribution of the Surgical Navigation Robot, NaoTrac, throughout the region of GCC region,Jordan, Egy...
2022-09-12 08:31
2593
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022
* Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients * For patients received initial dose over 3 months, the ORR is 80.6% and for patients received initial dose over 6 months the ORR is 86.7%, CR rate 40% * Lemzoparlimab does not require priming ...
2022-09-10 21:00
1924
WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers
SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in response to the increasing demand for complex injection dosag...
2022-09-09 20:00
1807
Antengene to Present at Upcoming Industry Conferences
SHANGHAI and HONG KONG, Sept. 9, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hem...
2022-09-09 14:43
1328
MGI Celebrates Grand Opening of Its New State-of-the-Art Demo Lab in Japan
TOKYO, Sept. 9, 2022 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a global life science leader and innovator, announced today on its first day of IPO inChina the grand opening of a new demonstration laboratory inTokyo, Japan, enhancing Japanese customers' experience. MGI has been expanding the oper...
2022-09-09 09:00
2579
KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO
SYDNEY, Sept. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentation a...
2022-09-09 06:00
2677
YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine
BEIJING, Sept. 8, 2022 /PRNewswire/ -- YishengBio Co., Ltd., ("YishengBio"), a biopharmaceutical company dedicated to discovery, development, manufacturing and commercialization of new generations of vaccines and therapeutic biologics, announced that the Company received the approvals from the re...
2022-09-08 21:33
2564
Nutromics raises US$14 million for its ground-breaking wearable diagnostic platform
MELBOURNE, Australia and SAN DIEGO, Sept. 8, 2022 /PRNewswire/ -- Global MedTech start-up Nutromics has raised an additional US$14 million for its wearable diagnostic platform. This transformative funding is key to Nutromics' continued expansion acrossAustralia and the United States. Strategic in...
2022-09-08 20:54
2456
ONE DRUG FOR ONE BUG: DEBIOPHARM TO DISCUSS THE POTENTIAL OF PATHOGEN-SPECIFIC ANTIBIOTICS AT THE 2022 WORLD AMR CONGRESS
* International health authorities, such as the WHO and the CDC are warning of the emerging danger of bacterial infections resistant to current antibiotics * The 2022 World Anti-Microbial Resistance (AMR) Congress in the greater Washington D.C. area is serving as a forum to openly address the ...
2022-09-08 16:41
1625
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 298 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 294 media titles]
2024-11-26 13:00Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9302
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
8977
